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CTX-M–type β-lactamases are increasing among US 
Enterobacteriaceae isolates. Of 2,165 non-Typhi Salmonella 
isolates submitted in 2007 to the National Antimicrobial Re-
sistance Monitoring System, 100 (4.6%) displayed elevated 
MICs (>2 mg/L) of ceftriaxone or ceftiofur. Three isolates (se-
rotypes Typhimurium, Concord, and I 4,5,12:i:–) contained 
blaCTX-M–5, blaCTX-M–15, and blaCTX-M–55/57, respectively.
S
evere non-Typhi Salmonella (NTS) infections are com-
monly treated with ﬂ  uoroquinolones such as ciproﬂ  oxa-
cin or, in children, with extended-spectrum cephalosporins 
such as ceftriaxone. The emergence of Salmonella spp. 
isolates that display resistance to extended-spectrum ce-
phalosporins is of increasing public health concern. In the 
United States, almost all resistance to extended-spectrum 
cephalosporins among Salmonella spp. isolates is caused by 
AmpC-type β-lactamases; extended-spectrum β-lactamases 
(ESBLs), including cefotaximases (CTX-M), rarely have 
been reported. Likewise, among other Enterobacteriaceae 
isolates in the United States, CTX-M enzymes have been 
considered rare until recently. 
In 2007, Lewis et al. reported that CTX-M was the 
predominant ESBL among Enterobacteriaceae isolates in 
a US health care system (San Antonio, TX) (1). Among 
the ESBL-producing isolates collected, CTX-M enzymes 
increased in prevalence from 25% in 2002 to 70% in 2006. 
The emergence was observed mainly in urinary tract iso-
lates of Escherichia coli, and the predominating enzyme 
was CTX-M-15 (1). Similarly, a US study investigating 
clinical samples of Enterobacteriaceae submitted to The 
Hospital of the University of Pennsylvania (Philadelphia, 
PA) in 2007 reported that 48% of cephalosporin-resistant 
E. coli isolates were CTX-M positive (2). Furthermore, 
CTX-M enzymes, and CTX-M-15 in particular, were com-
mon among ESBL-producing Enterobacteriaceae isolates 
collected at 15 US medical centers participating in the 
Meropenem Yearly Susceptibility Test Information Col-
lection Program during 2007 (3).
In the United States, the National Antimicrobial Re-
sistance Monitoring System (NARMS) has systemati-
cally monitored antimicrobial susceptibility of NTS since 
1996. This program is a collaborative effort between the 
Centers for Disease Control and Prevention (CDC), the 
Food and Drug Administration, and the US Department of 
Agriculture. Reports on increased prevalence of CTX-M 
enzymes among Enterobacteriaceae isolates in the United 
States prompted us to investigate CTX-M enzymes among 
NARMS NTS isolates collected from humans in 2007.
The Study
In 2007, public health laboratories in all US state 
health departments submitted every twentieth NTS isolated 
from humans to CDC for susceptibility testing by NARMS. 
MICs were determined by using broth microdilution (Sen-
sititer, Trek Diagnostics, Westlake, OH, USA) and inter-
preted according to Clinical Laboratory Standards Institute 
criteria, where available.
Of the 2,165 human NTS isolates submitted to NARMS 
in 2007, a total of 100 (4.6%) displayed elevated MICs (>2 
mg/L) of ceftriaxone or ceftiofur, extended-spectrum ce-
phalosporins used in human and veterinary medicine, re-
spectively. Genomic DNA prepared from the 100 isolates 
and a PCR screen obtained by using degenerate primers ca-
pable of detecting all CTX-M enzymes identiﬁ  ed 3 positive 
isolates, including serotypes Typhimurium; I 4,5,12:i:–; 
and Concord (4). Most (66%) of the remaining 97 isolates 
harbored a blaCMY gene.
The 3 CTX-M–producing Salmonella spp. infections 
occurred in 2 female patients (8 months of age and 72 years 
of age) and 1 male patient (1 year of age). Interviews were 
available for 2 patients, the 8-month-old (her parents) and 
the 72-year-old; in both instances, gastrointestinal symp-
toms with diarrhea were reported, and medical care was 
sought. Both patients received antimicrobial drug treatment 
(azithromycin and levoﬂ  oxacin, respectively). The 72-year-
old patient had traveled internationally before illness onset; 
the 8-month-old patient, who was infected with S. enterica 
serovar Concord, was an adoptee from Ethiopia.
All 3 isolates displayed resistance to β-lactams and 
extended-spectrum cephalosporins (Table). The S. enterica 
serovar Typhimurium and Concord isolates displayed addi-
tional multiresistance phenotypes. In addition, the serovar 
Typhimurium isolate displayed resistance to the quinolone 
nalidixic acid, a resistance phenotype associated with 
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Typhimurium and Concord isolates showed decreased 
susceptibility to ciproﬂ  oxacin (MIC 0.25 mg/L and 0.125 
mg/L, respectively). PCR for the plasmid-mediated mecha-
nisms qnrA,B,S and aac(6′)Ib-cr showed a qnrA gene in the 
serovar Concord isolate. Sequencing conﬁ  rmed qnrA1.
Group-speciﬁ  c PCR primers were used to characterize 
the presumed blaCTX-M genes (5). S. enterica serovar Con-
cord and I 4,5,12:i:– harbored group I enzymes, whereas the 
S. enterica serovar Typhimurium isolate harbored a group 
II enzyme. Sequencing showed blaCTX-M-15 in the serovar 
Concord isolate, blaCTX-M-5 in the serovar Typhimurium 
isolate, and blaCTX-M-55/57 in the serovar I 4,5,12:i:– isolate. 
Presence of other β-lactamase–encoding genes (blaTEM, 
blaSHV, blaCMY, blaPSE, and blaOXA) was investigated by us-
ing PCR (6–9). Ampliﬁ  cation and sequencing conﬁ  rmed a 
blaOXA-1 and a blaSHV-12 gene in the serovar Typhimurium 
and Concord isolates, respectively (7,8).
The genetic environment of each blaCTX-M gene was in-
vestigated by using PCR aimed at identifying insertion ele-
ments ISEcpI, IS26, and CR1 (formerly known as orf513) 
(10). Ampliﬁ  cation and sequencing of the PCR products 
conﬁ  rmed the ISEcp1 element upstream of each blaCTX-M 
gene (10). In addition to ISEcp1, an IS26 element was de-
tected upstream of the blaCTX-M-5 and blaCTX-M-15 genes.
To determine whether the CTX-M enzymes were 
plasmid borne, we extracted and transformed plasmids 
into electrocompetent E. coli DH10B. The blaCTX-M-55/57 
gene transferred to E. coli; repeated attempts to transfer 
the blaCTX-M-5 and blaCTX-M-15 genes were unsuccessful. PCR 
ampliﬁ  cation and plasmid pulsed-ﬁ  eld gel electrophoresis 
conﬁ  rmed the presence of the blaCTX-M-55/57 gene on a 70-kb 
plasmid in the transformant. The plasmid was not typeable 
by PCR-based incompatibility/replicon typing.
Conclusions
We describe 3 CTX-M–producing isolates of NTS 
collected from humans in the United States during 2007. 
CTX-M–producing Salmonella spp. previously have been 
reported among the NARMS collection of human isolates. 
The ﬁ  rst isolate was S. enterica serovar Typhimurium from 
a 3-month-old child in Georgia in 2003 (11). This infection 
was considered domestically acquired because the child’s 
family did not report a history of international travel. In ad-
dition, a CTX-M-15–producing isolate of S. enterica sero-
var Concord was identiﬁ  ed among NARMS NTS collected 
in 2006 (12). However, in contrast to the previous case, 
this infection most likely was acquired abroad because the 
patient reported travel to Ethiopia in conjunction with ill-
ness onset.
At least 1 of the infections described in the present study 
probably was acquired abroad; the CTX-M-15–producing 
S.  enterica  serovar Concord isolate was isolated from 
an adopted child from Ethiopia. Thus, both instances of 
CTX-M–producing serovar Concord isolates identiﬁ  ed 
in NARMS thus far have been associated with travel to 
Ethiopia. The emergence of CTX-M-15–producing serovar 
Concord infections among Ethiopian adoptees has been de-
scribed previously (13). In addition, the emergence of se-
rovar Concord isolates that produced CTX-M-15, SHV-12, 
and QnrA1 was recently described (14).
The fact that blaCTX-M genes commonly are located on 
plasmids and in conjunction with mobile genetic elements 
such as ISEcpI most likely has contributed to their dissemi-
nation. The blaCTX-M-55/57 gene that was transferable to E. coli 
in the present study was located on a 70-kb plasmid. The 
fact that the blaCTX-M-5 and blaCTX-M-15 gene did not transfer 
might suggest chromosomal locations. In fact, Fabre et al. 
found that most CTX-M–15–producing S. enterica serovar 
Concord isolates studied harbored the blaCTX-M gene on the 
chromosome (13).
The recently reported increase in CTX-M–producing 
Enterobacteriaceae in the United States raises concern. 
First, a reservoir of ESBLs and CTX-M genes among E. 
coli and Klebsiella spp. constitutes a risk factor for in-
creased spread of resistance to other pathogenic bacteria, 
including Salmonella spp. Second, use of cephalosporins to 
treat serious ESBL-producing bacterial infections has been 
associated with high rates of treatment failure (15). Thus, 
an increase in CTX-M–producing Salmonella spp. strains 
is likely to directly affect treatment, especially among chil-
dren for whom use of ﬂ  uoroquinolones is contraindicated. 
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AM33608 Typhimurium SC AMP, AUG, CHL, 
CTX, NAL, SUL, 
SXT, XNL
64 CTX-M-5, OXA-1 – ND No
AM32667 I 4,5,12:i:– CT AMP, CTX, XNL 64 CTX-M-55/57 – No Yes
AM32764 Concord OR AMP, CHL, CTX, 
GEN, STR, SUL, 
SXT, TET, XNL
64 CTX-M-15, SHV-12 qnrA1 Ethiopia No
*CTX, ceftriaxone; AMP, ampicillin; AUG, amoxicillin-clavulanic acid; CHL, chloramphenicol; NAL, nalidixic acid; SUL, sulfamethoxazole or sulfisoxazole; 
SXT, trimethoprim–sulfamethoxazole; XNL, ceftiofur; –, none detected; ND, not determined; GEN, gentamicin; STR, streptomycin; TET, tetracycline. CTX-M–producing Non-Typhi Salmonella spp., USA
Moreover, the decreased susceptibility to ciproﬂ  oxacin of 
the serovar Typhimurium and Concord isolates in the pres-
ent study raises concern about the emergence of isolates 
showing concurrent resistance to both extended-spectrum 
cephalosporins and ﬂ  uoroquinolones. Continued surveil-
lance of resistant bacteria, in combination with prudent use 
of antimicrobial agents in animals and humans, is crucial 
for limiting further spread of CTX-M–producing isolates 
of Enterobacteriaceae in the United States.
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